Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cefixime.

N J Leggett1, C Caravaggio, M J Rybak

  • 1College of Pharmacy and Allied Health Professions, Wayne State University, Detroit, MI 48202.

DICP : the Annals of Pharmacotherapy
|May 1, 1990
PubMed
Summary
This summary is machine-generated.

Cefixime, a third-generation cephalosporin antibiotic, shows broad-spectrum efficacy against many bacterial infections, including respiratory and genitourinary tract infections. Clinical trials indicate low resistance and mild side effects, making it a promising oral treatment option.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multicenter Study of the Real-World Use of Ceftaroline versus Vancomycin for Acute Bacterial Skin and Skin Structure Infections.

Antimicrobial agents and chemotherapy·2019
Same author

Impact of High-Level Daptomycin Resistance in the Streptococcus mitis Group on Virulence and Survivability during Daptomycin Treatment in Experimental Infective Endocarditis.

Antimicrobial agents and chemotherapy·2017
Same author

Defining daptomycin resistance prevention exposures in vancomycin-resistant Enterococcus faecium and E. faecalis.

Antimicrobial agents and chemotherapy·2014
Same author

Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA.

Antimicrobial agents and chemotherapy·2013
Same author

Independent risk factors for the co-colonization of vancomycin-resistant Enterococcus faecalis and methicillin-resistant Staphylococcus aureus in the region most endemic for vancomycin-resistant Staphylococcus aureus isolation.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2013
Same author

Successful treatment of a left ventricular assist device infection with daptomycin non-susceptible methicillin-resistant Staphylococcus aureus: case report and review of the literature.

Transplant infectious disease : an official journal of the Transplantation Society·2012
Same journal

Eradication of methicillin-resistant Staphylococcus aureus vaginitis with mupirocin.

DICP : the annals of pharmacotherapy·1991
Same journal

Ketorolac formulary restriction and usage evaluation.

DICP : the annals of pharmacotherapy·1991
Same journal

Oral vancomycin-induced rash: case report and review of the literature.

DICP : the annals of pharmacotherapy·1991
Same journal

Imipenem/cilastatin drug utilization evaluation in a large community hospital.

DICP : the annals of pharmacotherapy·1991
Same journal

Pharmacist involvement in Society of Critical Care Medicine.

DICP : the annals of pharmacotherapy·1991
Same journal

Early anticoagulation therapy in deep vein thrombosis.

DICP : the annals of pharmacotherapy·1991
See all related articles

Area of Science:

  • Pharmacology
  • Microbiology
  • Infectious Diseases

Background:

  • Cefixime is an orally active third-generation cephalosporin antibiotic.
  • It exhibits a broad spectrum of activity against numerous gram-positive and gram-negative bacteria.
  • Notably, it is effective against many beta-lactamase-producing strains, including *Streptococcus* species, *Haemophilus influenzae*, *Neisseria gonorrhoeae*, and most *Enterobacteriaceae*.

Purpose of the Study:

  • To evaluate the efficacy and safety of cefixime.
  • To assess its pharmacokinetic profile, particularly its elimination half-life.
  • To compare its effectiveness against standard treatments for specific infections.

Main Methods:

  • Clinical trials were conducted to assess cefixime's effectiveness.

Related Experiment Videos

  • Patient compliance was evaluated based on administration frequency.
  • Adverse reactions were systematically recorded and analyzed.

    • Main Results:

    • Cefixime demonstrated efficacy comparable to standard agents in treating genitourinary and upper respiratory tract infections.
    • The incidence of resistant organisms during trials was low.
    • Adverse reactions were generally mild and transient, with diarrhea and stool changes reported in up to 20% of patients.

    Conclusions:

    • Cefixime is an effective and well-tolerated oral antibiotic for common bacterial infections.
    • Its favorable pharmacokinetic profile allows for convenient once- or twice-daily dosing, potentially improving patient compliance.
    • The low incidence of resistance and mild side effect profile support its use in clinical practice.